Preliminary Study of P53 and C-erbB-2 Expression in Gallbladder Cancer in Indian Patients Manuscript Id: 8962091628764582

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2006 May 12

PMID 16686942

Citations 21

Authors

Amita Chaube

Mallika Tewari

R S Garbyal

Usha Singh

Hari S Shukla

Affiliations

Soon will be listed here.

Abstract

Background: The inactivation of the tumour suppressor gene and activation of the proto-oncogene are the key steps in the development of the human cancer. The p53 and c-erbB-2 are the best examples of it. In the present study, our aim was to determine the role of these genes in the carcinogenesis of gallbladder by immunohistochemistry.

Methods: In all 78 consecutive patients of gall bladder diseases were studied for p53 and c-erbB-2 expression immunohistochemically and their expression was correlated with the age, grades and stages of the disease and presence of stone. An informed consent was obtained in each case. Chi square and z test were applied to see the association of p53 and c-erbB-2 over expression with other clinicopathological factors.

Results: Eight (20%) patients of gall bladder cancer were positive for p53 expression and 10 (25%) patients for c-erbB-2. The p53 positivity increased with increasing grade while cerbB-2 positivity decreased with increasing grade of gall bladder cancer. Mean age in cerbB-2 positive cases were lesser as compared to negative cases while p53 did not show such association with age.

Conclusion: Only one case of gall bladder cancer co-expressed the p53 and c-erbB-2, thereby suggesting that p53 and c-erbB-2 may have independent role in carcinogenesis of gall bladder cancer. c-erbB-2 over expression in adenoma and younger age group indicates its role as an early event in carcinogenesis of gallbladder. However study of larger sample is required to further validate the results.

Citing Articles

Human epidermal growth factor receptor-2/neu expression in gallbladder cancer is significantly associated with clinicopathological parameters and survival.

Dash S, Anirvan P, Samantaray S, Swain P, Parida P, Rout N Indian J Gastroenterol. 2025; .

PMID: 39899204 DOI: 10.1007/s12664-024-01723-x.

HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma.

Chen L, Xu L, Shen L, Luo R, Jiang D, Wang Y Front Genet. 2022; 12:831318.

PMID: 35265100 PMC: 8899850. DOI: 10.3389/fgene.2021.831318.

Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma.

Sung Y, Kim S, Jun S, Yoo C, Kim K, Lee J Front Oncol. 2021; 11:658564.

PMID: 34367955 PMC: 8339709. DOI: 10.3389/fonc.2021.658564.

Expression of Human epidermal growth factor receptor 2, Survivin, Enhancer of zeste homolog -2, Cyclooxygenase-2, p53 and p16 molecular markers in Gall bladder carcinoma.

Gupta A, Gupta S, Mani R, Durgapal P, Goyal B, Rajput D J Carcinog. 2021; 20:7.

PMID: 34321957 PMC: 8312376. DOI: 10.4103/jcar.JCar_4_21.

Overview of current targeted therapy in gallbladder cancer.

Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y Signal Transduct Target Ther. 2020; 5(1):230.

PMID: 33028805 PMC: 7542154. DOI: 10.1038/s41392-020-00324-2.

References

Di Marco E, PIERCE J, Knicley C, Di Fiore P . Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol Cell Biol. 1990; 10(6):3247-52. PMC: 360691. DOI: 10.1128/mcb.10.6.3247-3252.1990. View

Kim Y, Huh S, Park Y, Yoon T, Lee S, Hong S . Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep. 2001; 8(5):1127-32. DOI: 10.3892/or.8.5.1127. View

Albores-Saavedra J, Henson D, Sobin L . The WHO Histological Classification of Tumors of the Gallbladder and Extrahepatic Bile Ducts. A commentary on the second edition. Cancer. 1992; 70(2):410-4. DOI: 10.1002/1097-0142(19920715)70:2<410::aid-cncr2820700207>3.0.co;2-r. View

Oxley da Rocha A, Barbosa Coutinho L, Scholl J, Leboutte L . The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases. Hepatogastroenterology. 2004; 51(59):1310-4. View

Misra S, Chaturvedi A, Goel M, Mehrotra R, Sharma I, Srivastava A . Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol. 2000; 26(2):164-7. DOI: 10.1053/ejso.1999.0763. View

Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C . Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology. 2005; 46(4):431-41. DOI: 10.1111/j.1365-2559.2005.02112.x. View

Dhir V, Mohandas K . Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol. 1999; 18(1):24-8. View

Yukawa M, Fujimori T, Hirayama D, Idei Y, Ajiki T, Kawai K . Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. Hum Pathol. 1993; 24(1):37-40. DOI: 10.1016/0046-8177(93)90060-t. View

Ralhan R, Agarwal S, Nath N, Mathur M, Wasylyk B, Srivastava A . Correlation between p53 gene mutations and circulating antibodies in betel- and tobacco-consuming North Indian population. Oral Oncol. 2001; 37(3):243-50. DOI: 10.1016/s1368-8375(00)00092-0. View

10.

Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y . Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg. 2000; 7(2):198-205. DOI: 10.1007/s005340050176. View

11.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

12.

Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y . p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol. 1993; 170(1):67-72. DOI: 10.1002/path.1711700111. View

13.

Chow N, Huang S, Chan S, Mo L, Hwang M, Su W . Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res. 1995; 15(3):1055-9. View

14.

Billo P, MARCHEGIANI C, Capella C, Sessa F . [Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa]. Pathologica. 2000; 92(4):249-56. View

15.

Neugut A . Diagnostic and management issues in gallbladder carcinoma. Oncology (Williston Park). 1995; 9(1):19-24; discussion 24, 27, 30. View

16.

Steele R, Thompson A, Hall P, Lane D . The p53 tumour suppressor gene. Br J Surg. 1998; 85(11):1460-7. DOI: 10.1046/j.1365-2168.1998.00910.x. View

17.

Wanebo H, Vezeridis M . Carcinoma of the gallbladder. J Surg Oncol Suppl. 1993; 3:134-9. DOI: 10.1002/jso.2930530536. View

18.

Suzuki T, Takano Y, Kakita A, Okudaira M . An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. Pathol Res Pract. 1993; 189(3):283-92. DOI: 10.1016/S0344-0338(11)80511-X. View

19.

Ireland A, Clark G, DeMeester T . Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg. 1997; 225(1):17-30. PMC: 1190601. DOI: 10.1097/00000658-199701000-00003. View

20.

Kalekou H, Miliaras D . Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. J Gastroenterol Hepatol. 2004; 19(7):812-8. DOI: 10.1111/j.1440-1746.2004.03357.x. View